Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | PTPN2 | P17706 | 3/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5395150 | 0.83 | PTPN1 (0.46) | PTPN2PTPN1 | |
| SCHEMBL7182954 | 0.80 | PTPN2 (0.33) | GAALMNAPOLBPTPN2PTPN1 | |
| SCHEMBL4007816 | 0.75 | PTPN1 (0.48) | NPSR1PTPN2PTPN1 | |
| SCHEMBL3741679 | 0.74 | PTPN1 (0.41) | LMNAPOLBPTPN2PTPN1 | |
| SCHEMBL14626948 | 0.74 | HRH3 (0.31) | — | |
| SCHEMBL3737637 | 0.74 | PTPN1 (0.45) | GAANPSR1LMNAALDH1A1PTPN2 | |
| SCHEMBL3739163 | 0.74 | PTPN1 (0.34) | GAANPSR1LMNAALDH1A1PTPN2 | |
| SCHEMBL7187493 | 0.73 | PTPN1 (0.37) | GAANPSR1LMNAPOLBALDH1A1 | |
| SCHEMBL4005573 | 0.73 | GAA (0.38) | GAAPTPN2PTPN1KMT2AMEN1 | |
| SCHEMBL3740770 | 0.72 | NOTUM (0.45) | LMNAPOLBALDH1A1PTPN2PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7163932-B2 | Aryldifluoromethylphosphonic acids for treatment of diabetes | MERCK FROSST CANADA & CO. (CA) | 2007-01-16 | — | — | US | disclosed |
| US-20040176330-A1 | Aryldifluoromethylphosphonic acids for treatment of diabetes | MERCK FROSST CANADA LTD. (CA) | 2004-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176330-A1 | Aryldifluoromethylphosphonic acids for treatment of diabetes | PTPRF, PTPRO, PTP4A1 | GAA 135/4885NPSR1 2994/4885LMNA 4552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.